Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Tirzepatide is a once-weekly prescription weight-loss injection approved as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes. It activates both GIP and GLP-1 receptors to reduce appetite and improve blood sugar. In SURMOUNT-1, the highest dose studied was linked with 20.9% average weight loss over 72 weeks; individual results vary, and GI side effects are common [1][2][6].
Tirzepatide is part of a larger group of injectable metabolic medications. For a plain-English overview of the class, see our guide to GLP-1 medications.
What is tirzepatide?
Tirzepatide is a lab-made peptide medication developed by Eli Lilly. It is approved by the FDA under two brand names: Mounjaro for adults with type 2 diabetes and Zepbound for chronic weight management in adults with obesity, or overweight plus at least one weight-related condition [1][2]. The FDA approved Mounjaro in 2022 and Zepbound in 2023 [1][2].
Tirzepatide is often described as a dual incretin medication because it activates two hormone receptors: glucose-dependent insulinotropic polypeptide, or GIP, and glucagon-like peptide-1, or GLP-1 [3]. This makes it different from semaglutide, the active ingredient in Wegovy and Ozempic, which mainly acts on the GLP-1 receptor [11][14].
Compounded tirzepatide may also be dispensed by licensed 503A compounding pharmacies for individual patients when clinically appropriate. Compounded tirzepatide is not FDA-approved, and the FDA has not reviewed compounded versions for safety, effectiveness, or manufacturing quality [10].
How does tirzepatide work for weight loss?
The GIP and GLP-1 dual mechanism
Tirzepatide activates both the GIP receptor and the GLP-1 receptor. These hormone pathways help regulate appetite, insulin release, and how quickly food leaves the stomach [1][3]. The dual mechanism is one reason tirzepatide has produced large average weight-loss results in trials lasting 72 weeks [6].
GLP-1 receptor activity helps increase fullness, slow stomach emptying, and support glucose-dependent insulin release [1][3]. GIP receptor activity may add effects on insulin response, appetite signaling, and fat metabolism, though researchers are still studying the exact role of GIP in weight loss [3][4].
The same pathways that help with appetite can also cause side effects. Nausea, diarrhea, constipation, vomiting, and abdominal pain are common, especially during dose escalation in the FDA labels and clinical trials [1][2][6]. Tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma, or MTC, or Multiple Endocrine Neoplasia syndrome type 2, or MEN 2 [1][2].
Effects on appetite and blood sugar
- Tirzepatide slows gastric emptying, so food may stay in the stomach longer [1][2].
- It acts on appetite pathways that help people feel full with less food [3][6].
- It helps the pancreas release insulin when blood sugar is high, which is why Mounjaro is approved for type 2 diabetes [1].
- It may reduce fasting and after-meal blood sugar in people with type 2 diabetes [1][7].
- Low blood sugar is more likely when tirzepatide is used with insulin or sulfonylureas [1][2].
Is tirzepatide the same as Mounjaro or Zepbound?
Mounjaro and Zepbound contain the same active ingredient: tirzepatide. The main difference is the FDA-approved use. Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity [1][2][5]. Both are once-weekly injections with labeled strengths up to 15 mg [1][2].
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide [1] | Tirzepatide [2] |
| FDA-approved use | Adults with type 2 diabetes, as an addition to diet and exercise [1] | Chronic weight management; moderate-to-severe obstructive sleep apnea in adults with obesity [2][5] |
| Manufacturer | Eli Lilly [1] | Eli Lilly [2] |
| Drug class | Dual GIP and GLP-1 receptor agonist [1] | Dual GIP and GLP-1 receptor agonist [2] |
| Labeled strengths | 2.5, 5, 7.5, 10, 12.5, and 15 mg [1] | 2.5, 5, 7.5, 10, 12.5, and 15 mg [2] |
| Boxed warning | Thyroid C-cell tumors; contraindicated with personal or family history of MTC or MEN 2 [1] | Thyroid C-cell tumors; contraindicated with personal or family history of MTC or MEN 2 [2] |
Using Mounjaro for weight loss alone in a person without type 2 diabetes is an off-label use. Zepbound is the on-label tirzepatide brand for chronic weight management [2]. For a deeper brand-specific review, see our Mounjaro guide.
How much weight can you lose on tirzepatide?
Clinical trial results from SURMOUNT
In SURMOUNT-1, researchers studied tirzepatide in 2,539 adults with obesity or overweight plus a weight-related condition who did not have diabetes. In that trial, participants received once-weekly tirzepatide doses of 5 mg, 10 mg, or 15 mg, plus lifestyle counseling, for 72 weeks [6]. Individual results vary, and gastrointestinal side effects were common [6].
| Dose studied in SURMOUNT-1 | Mean body-weight change at 72 weeks |
|---|---|
| 5 mg once weekly | About -15.0% [6] |
| 10 mg once weekly | About -19.5% [6] |
| 15 mg once weekly | About -20.9% [6] |
| Placebo | About -3.1% [6] |
In SURMOUNT-2, researchers studied adults with obesity or overweight and type 2 diabetes. Participants receiving tirzepatide had average weight loss of about 12.8% with 10 mg and 14.7% with 15 mg over 72 weeks [7]. Weight loss is often smaller in people with type 2 diabetes than in people without diabetes, and side effects and contraindications still apply [1][2][7].
Typical timeline for results
Tirzepatide studies show weight loss building over months, not days. In SURMOUNT-1, the main result was measured at 72 weeks, and weight loss continued through much of the study period [6].
- Early weeks: appetite may change early, but weight change is often modest while the body adjusts [1][2][6].
- Months 2 to 6: in trials, weight loss generally became more noticeable as participants continued therapy and lifestyle counseling [6][7].
- Months 6 to 18: many participants continued losing weight before approaching a plateau [6].
- After stopping: in SURMOUNT-4, participants who switched from tirzepatide to placebo regained weight during the following year [8].
Trial results are averages. Some people lose more, some lose less, and some stop treatment because of side effects [6][8]. A clinician should also screen for risks such as pancreatitis, gallbladder disease, severe gastrointestinal disease, pregnancy, and thyroid cancer history [1][2].
What is the tirzepatide dosing schedule?
Starting dose and titration
The FDA-approved labels for Mounjaro and Zepbound describe tirzepatide as a once-weekly subcutaneous injection. The labeled starting dose is 2.5 mg once weekly for 4 weeks, followed by gradual increases when clinically appropriate [1][2]. This is label information, not a personal dosing plan.
| FDA-label stage | Dose described on the FDA label |
|---|---|
| First 4 weeks | 2.5 mg once weekly as the starting dose; the label states this dose is for treatment initiation and not intended for glycemic control [1][2] |
| After 4 weeks | 5 mg once weekly is the next labeled dose [1][2] |
| Further titration | The FDA labels describe 2.5 mg increases after at least 4 weeks on the current dose when additional response is needed and tolerated [1][2] |
| Maximum labeled dose | 15 mg once weekly [1][2] |
Maintenance dose
The FDA-approved maintenance doses listed on the Zepbound label are 5 mg, 10 mg, or 15 mg once weekly [2]. For Mounjaro, the FDA label lists maintenance doses from 5 mg to 15 mg once weekly for glycemic control in adults with type 2 diabetes [1].
Higher doses may produce more average weight loss in trials, but they may also increase nausea, vomiting, diarrhea, constipation, and treatment discontinuation [1][2][6]. The goal is not simply the highest dose; it is a dose a person can tolerate and benefit from under clinician supervision.
How do you use the tirzepatide injection?
Per the FDA labels, tirzepatide is given as a subcutaneous injection, meaning under the skin, once weekly [1][2]. Brand-name products are supplied as single-dose pens or vials depending on the product and presentation, while compounded tirzepatide is often dispensed in vials by licensed 503A pharmacies and is not FDA-approved [1][2][10]. For a broader primer, see our guide on how to inject GLP-1 medications.
Injection sites
- The FDA labels list the abdomen, thigh, or upper arm as injection areas [1][2].
- The labels advise using a different injection site each week when injecting in the same body region [1][2].
- The medicine can be given with or without food, according to the FDA labels [1][2].
- A clinician or pharmacist should teach injection technique before first use [1][2].
Storage and handling
- The FDA labels state that tirzepatide should be stored refrigerated at 36°F to 46°F, or 2°C to 8°C [1][2].
- The FDA labels state that brand-name tirzepatide may be kept at room temperature up to 86°F, or 30°C, for up to 21 days [1][2].
- The FDA labels state not to freeze tirzepatide and not to use it if it has been frozen [1][2].
- Needles and syringes should be disposed of in an FDA-cleared sharps container when possible [13].
What are the side effects of tirzepatide?
Gastrointestinal side effects
Tirzepatide commonly causes gastrointestinal side effects. In FDA-label trial data, these effects often happened during dose escalation and were usually mild to moderate, but some people stopped treatment because of them [1][2]. The Zepbound label reports nausea in up to 29% of adults in weight-management trials [2].
- Nausea [1][2]
- Diarrhea [1][2]
- Constipation [1][2]
- Vomiting [1][2]
- Abdominal pain [1][2]
- Indigestion, reflux, or burping [1][2]
- Decreased appetite [1][2]
- Injection-site reactions such as redness or itching [1][2]
For more detail on what is common, what is urgent, and how clinicians think about tolerability, see our guide to GLP-1 side effects.
Serious warnings and contraindications
Other serious risks listed in the FDA-approved labels include pancreatitis, gallbladder disease, acute kidney injury, severe gastrointestinal disease, hypoglycemia when used with insulin or sulfonylureas, serious allergic reactions, and worsening diabetic retinopathy in some people with type 2 diabetes [1][2].
- Pancreatitis: severe, persistent abdominal pain needs urgent medical attention [1][2].
- Gallbladder problems: rapid weight loss and GLP-1-based therapies can be linked with gallstones or gallbladder inflammation [1][2].
- Kidney injury: dehydration from vomiting or diarrhea can worsen kidney function [1][2].
- Severe gastrointestinal disease: tirzepatide is not recommended in people with severe GI disease, including severe gastroparesis [1][2].
- Hypoglycemia: risk is higher when used with insulin or sulfonylureas [1][2].
- Pregnancy: weight-loss medications are generally not used during pregnancy, and the Zepbound label advises discontinuation when pregnancy is recognized [2].
Who is eligible for tirzepatide?
For chronic weight management, the Zepbound label applies to adults with a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or abnormal cholesterol [2]. BMI is only one part of the decision.
- A clinician reviews BMI, weight history, medical conditions, and current medications [2].
- A clinician screens for contraindications such as personal or family history of medullary thyroid carcinoma or MEN 2 [1][2].
- A clinician asks about pancreatitis, gallbladder disease, severe gastroparesis, kidney disease, pregnancy plans, and diabetes medications [1][2].
- For Mounjaro, the FDA-approved use is type 2 diabetes, as an addition to diet and exercise [1].
Eligibility is not the same as automatic approval. For a broader checklist, see our guide to weight-loss medication eligibility.
3-min quiz
Wondering if you qualify?
A licensed clinician can review your BMI, medical history, medications, and goals to see whether tirzepatide or another option may be appropriate.
How much does tirzepatide cost?
Tirzepatide cost depends on the product, insurance coverage, pharmacy, and savings programs. Eli Lilly lists U.S. branded tirzepatide pricing at roughly $1,000 or more per month before insurance or savings, though actual out-of-pocket cost can be much lower or higher depending on coverage [9].
- Mounjaro coverage is more common when prescribed for type 2 diabetes, its FDA-approved indication [1][9].
- Zepbound coverage for chronic weight management varies by employer and insurance plan [2][9].
- Manufacturer savings or self-pay options may reduce out-of-pocket cost for eligible patients [9].
- Compounded tirzepatide may cost less, but it is not FDA-approved and has not been reviewed by FDA for safety, effectiveness, or quality [10].
Licensed telehealth providers, including Chia, can review eligibility and discuss FDA-approved and compounded options when appropriate. A 503A compounding pharmacy is a state-licensed pharmacy that prepares patient-specific medications, but compounded tirzepatide remains non-FDA-approved [10].
What are the main ways patients access tirzepatide?
Tirzepatide access usually depends on diagnosis, insurance, medication availability, and whether the clinician recommends an FDA-approved brand or a compounded medication. The safest path is one that includes a real clinical evaluation, pharmacy transparency, and follow-up for side effects within the first several months [1][2][10].
| Access path | What it may offer | Key considerations |
|---|---|---|
| Primary care clinician | Evaluation, lab review if needed, and prescription for FDA-approved brands when appropriate [1][2] | Insurance coverage for obesity medications may be limited [9] |
| Obesity medicine specialist or endocrinologist | More complex care for obesity, type 2 diabetes, thyroid history, pancreatitis history, or multiple medications [1][2] | Wait times and visit costs may be higher |
| Licensed telehealth provider | Remote evaluation, follow-up, and pharmacy coordination for FDA-approved or compounded options when appropriate [10] | Ask about clinician licensure, pharmacy credentials, testing, and side-effect support |
| Manufacturer self-pay or savings program | Potential reduced cash-pay pricing or savings for eligible patients [9] | Eligibility rules, dose availability, and insurance requirements can change [9] |
| Compounding pharmacy through a prescription | Patient-specific compounded medication when clinically appropriate [10] | Not FDA-approved; FDA has not reviewed safety, effectiveness, or quality [10] |
How is tirzepatide different from semaglutide?
Tirzepatide activates both GIP and GLP-1 receptors, while semaglutide is a GLP-1 receptor agonist [3][11]. Semaglutide is the active ingredient in Wegovy, Ozempic, and compounded semaglutide; Wegovy is FDA-approved for chronic weight management, while Ozempic is FDA-approved for type 2 diabetes and cardiovascular risk reduction in certain adults with type 2 diabetes [11][14].
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Common brand names | Zepbound, Mounjaro [1][2] | Wegovy, Ozempic [11][14] |
| Mechanism | Dual GIP and GLP-1 receptor agonist [3] | GLP-1 receptor agonist [11] |
| FDA-approved weight-management brand | Zepbound [2] | Wegovy [11] |
| Highest FDA-label dose for weight management | 15 mg once weekly for Zepbound [2] | 2.4 mg once weekly for Wegovy [11] |
| Key trial result | SURMOUNT-1: up to 20.9% mean weight loss at 72 weeks on 15 mg [6] | STEP 1: 14.9% mean weight loss at 68 weeks on 2.4 mg [15] |
| Common side effects | Nausea, diarrhea, constipation, vomiting, abdominal pain [1][2] | Nausea, diarrhea, vomiting, constipation, abdominal pain [11] |
| Boxed warning | Thyroid C-cell tumors [1][2] | Thyroid C-cell tumors [11] |
| Compounded versions | May be available, but not FDA-approved [10] | May be available, but not FDA-approved [10] |
In the SURMOUNT-5 head-to-head trial, adults with obesity or overweight without diabetes received tirzepatide or semaglutide for 72 weeks. Mean weight loss was 20.2% with tirzepatide and 13.7% with semaglutide; individual results vary, and both groups had gastrointestinal side effects [12]. For a brand-level comparison, see our Zepbound vs. Wegovy guide.
Both medicines require the same kind of safety review: thyroid cancer history, pancreatitis history, gallbladder disease, severe gastrointestinal disease such as gastroparesis, pregnancy status, kidney risk, and interacting diabetes medicines [1][2][11]. For a deeper semaglutide overview, see our guide to semaglutide for weight loss.
Frequently asked questions
Yes. Tirzepatide is the active ingredient in both Mounjaro and Zepbound. Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity [1][2][5].
Tirzepatide has GLP-1 activity, but it is not GLP-1-only. It is a dual GIP and GLP-1 receptor agonist, meaning it activates both receptors [3].
The Zepbound FDA label describes 2.5 mg once weekly for 4 weeks as the starting dose, followed by labeled maintenance doses of 5 mg, 10 mg, or 15 mg once weekly when clinically appropriate [2]. This is educational label information, not personal dosing advice.
In SURMOUNT-1, weight loss was measured over 72 weeks and generally increased over time [6]. Some people notice appetite changes earlier, but weight-loss response varies, and side effects such as nausea or diarrhea can affect tolerability [1][2][6].
In SURMOUNT-4, participants who continued tirzepatide maintained and lost more weight, while those switched to placebo regained weight during the following year [8]. Obesity is a chronic condition, so stopping medication should be discussed with a clinician.
The FDA labels warn about acute pancreatitis and state that tirzepatide is not recommended in people with severe gastrointestinal disease, including severe gastroparesis [1][2]. Severe or persistent abdominal pain, repeated vomiting, or dehydration needs prompt medical care.
No. Compounded tirzepatide is not FDA-approved, and FDA has not reviewed compounded versions for safety, effectiveness, or quality [10]. It should only be considered through a licensed clinician and a properly credentialed pharmacy.
Yes, licensed telehealth clinicians can evaluate eligibility and prescribe tirzepatide when appropriate. AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health.
3-min quiz
Talk to a clinician about weight-loss injections
If you are considering tirzepatide, a licensed clinician can review your BMI, health history, medications, side-effect risks, and treatment goals before deciding whether a prescription is appropriate.
References
- 1.U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information, 2022.
- 2.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information, 2023.
- 3.Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 2018.
- 4.Samms RJ, Christe ME, Collins KA, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Journal of Clinical Investigation, 2021.
- 5.U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea, 2024.
- 6.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022.
- 7.Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 2023.
- 8.Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA, 2024.
- 9.Eli Lilly and Company. Mounjaro and Zepbound pricing, savings, and access information, 2026.
- 10.U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss, 2025.
- 11.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information, 2021.
- 12.Aronne LJ, Jastreboff AM, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine, 2025.
- 13.U.S. Food and Drug Administration. Safely using sharps, needles, and syringes at home, at work, and on travel, 2024.
- 14.U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information, 2017.
- 15.Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
